The ELUCIDATE FFRct Study
Status: Recruiting
Location: See all (9) locations...
Intervention Type: Device
Study Type: Observational
SUMMARY
The goal of this study is to evaluate the diagnostic accuracy of a novel plaque-based coronary CT angiography (CCTA) fractional flow reserve (FFRct) software device for the estimation of invasive fractional flow reserve (FFR). Researchers will compare the Elucid plaque-based FFRct analysis to invasively measured FFR in patients who have previously undergone CCTA and invasively assessed FFR.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• \- Adults \>=18 years with at least one 30-90% stenosis on CCTA (\>64- detector row) performed within 60 days of undergoing invasive FFR.
Locations
United States
California
Cardiovascular Medical Group of Southern California
NOT_YET_RECRUITING
Beverly Hills
Georgia
Piedmont Healthcare
NOT_YET_RECRUITING
Atlanta
Indiana
Parkview Health
NOT_YET_RECRUITING
Fort Wayne
Kansas
Midwest Heart and Vascular Specialists
RECRUITING
Overland Park
New Jersey
Valley Health System
NOT_YET_RECRUITING
Ridgewood
Ohio
Cleveland Clinic
NOT_YET_RECRUITING
Cleveland
Tennessee
Ascension Medical Group
NOT_YET_RECRUITING
Nashville
Centennial Heart
NOT_YET_RECRUITING
Nashville
Virginia
University of Virginia
RECRUITING
Charlottesville
Contact Information
Primary
Todd C Villines, MD
todd.villines@elucid.com
978-468-0508
Backup
John Aluru, MBBS
john.aluru@elucid.com
978-468-0508
Time Frame
Start Date: 2023-09-01
Estimated Completion Date: 2024-07-31
Participants
Target number of participants: 350
Treatments
Low FFR
Invasive FFR \<= 0.80
High FFR
Invasive FFR \> 0.80
Related Therapeutic Areas
Sponsors
Leads: Elucid Bioimaging Inc.
Collaborators: Lundquist Institute at Harbor-UCLA Medical Center